Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nutt D.J., King L.A., Nichols D.E. Nature Reviews Neuroscience, 2013, 14, 577-585 DOI : 10.1038/nrn3530 Abstract Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4‑methylenedioxy- N‑methyl-amphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteMechanisms of Therapeutic Action of Psilocybin Cubensis in Treating Patients with Depression Stephan Tap, Universiteit Leiden, Sociale Wetenschappen, 2018 Introduction Depression is a serious mental illness affecting over 300 to 350 million people worldwide (WHO, 2018; Cipriani et al., 2018). People suffering from depression experience a wide variety of symptoms, including a depressed mood, loss of interest, and reduced energy. There are many different therapeutic approaches to treat depression, of which cognitive behavioral therapy (CBT) and the use of antidepressants (e.g. SSRI’s) are probably the most prominent. Both seem to be efficacious in alleviating the symptoms of depression (Butler et al., 2006; Driessen & [...]
Lire la suiteIntérêt de la psilocybine, de l’acide lysergique diéthylamide (LSD) et de la diméthyltryptamine (DMT) dans la dépression : une revue de la littérature THÈSE MÉDECINE SPÉCIALISÉE CLINIQUE en Psychiatrie Présentée et soutenue publiquement par Sami SERGENT le 22 février 2019 ANNÉE 2019 (2019 TOU3 1503) Directeur de thèse : Dr François MONTASTRUC JURY Monsieur le Professeur Christophe ARBUS Président Monsieur le Professeur Laurent SCHMITT Assesseur Monsieur le Professeur Nicolas FRANCHITTO Assesseur Monsieur le Docteur François MONTASTRUC Assesseur Madame le Docteur Bénédicte JULLIAN Suppléant Monsieur le Docteur Nicolas NAVARRO membre invité RESUME EN FRANÇAIS : La psilocybine, l’acide lysergique diéthylamide et la diméthyltryptamine sont des psychédéliques agonistes sérotoninergiques. Les sociétés humaines en font usages depuis [...]
Lire la suiteEDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteBrain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users. Aviv Weinstein, Abigail Livny, Abraham Weizman. Current Pharmaceutical Design, 2016, 22, 42, 6366-6379. doi: 10.2174/1381612822666160822151323. PMID : 27549374 Abstract Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, psychotic symptoms and neurocognitive impairments and their neural mechanisms need to be examined. This review summarizes and critically evaluates brain-imaging studies of cannabis in recreational and regular cannabis users between January 2000 and January 2016. The [...]
Lire la suiteDynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin Louis-David Lord, Paul Expert, Selen Atasoy, Leor Roseman, Kristina Rapuano, Renaud Lambiotte, David J. Nutt, Gustavo Deco, Robin L. Carhart-Harris, Morten L. Kringelbach, Joana Cabral, NeuroImage, 2019, 199, 127–142 https://doi.org/10.1016/j.neuroimage.2019.05.060 A B S T R A C T Growing evidence from the dynamical analysis of functional neuroimaging data suggests that brain function can be understood as the exploration of a repertoire of metastable connectivity patterns (‘functional brain networks’), which potentially underlie different mental processes. The present study characterizes how the brain's dynamical exploration of resting-state networks is rapidly modulated by intravenous [...]
Lire la suitePilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano and Roland R Griffiths Journal of Psychopharmacology, 2014, Vol. 28(11) 983–992 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114548296 Abstract Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an openlabel pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment [...]
Lire la suitePsychological variables implied in the therapeutic effect of ayahuasca : a contextual approach. Alba Franquesa, Alberto Sainz-Cort, Sam Gandy, Joaquim Soler, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Psychiatry Research, 2017 PII: S0165-1781(17)31377-X DOI: 10.1016/j.psychres.2018.04.012 Abstract Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological [...]
Lire la suiteLong-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]
Lire la suite